Market Overview:
The global major tranquilizers market is expected to grow at a CAGR of 5.5% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing prevalence of mental disorders, such as schizophrenia, bipolar disorder, unipolar depression, and dementia. In addition, the growing awareness about mental health disorders and their treatment is also contributing to the growth of this market. The global major tranquilizers market can be segmented on the basis of type into first generation, second generation, and third generation drugs. The first generation drugs are those that were introduced in the 1950s and 1960s. These drugs are mainly used for treating schizophrenia and bipolar disorder. The second generation drugs were introduced in 1980s and 1990sand are mainly used for treating unipolar depression and anxiety disorders.
Product Definition:
A class of psychiatric drugs used to treat anxiety, insomnia, and agitation. Major tranquilizers are also known as antipsychotics or neuroleptics. They work by blocking certain receptors in the brain, which reduces the symptoms of psychosis or mania.
First Generation:
First generation or 1G is a type of sedative-hypnotic drug. It was first developed by Merck in the year 1915 and today it is manufactured by almost all pharmaceutical companies. The most common types of this drug are Halcion (triazolam), Valium (diazepam) and Ativan (lorazepam).
Second Generation:
Second generation is the latest and most advanced type of Tranquilizer. It was first developed in 1960 by a group of Swiss researchers at the University of Zurich. The drug was patented under the name "Iproniazid". The generic name for this drug is usually IPC (Isopropylphenidate). This drug has been extensively used as an anti-anxiety medication, but with recent technological advancements it can be used for major depressive disorder as well.
Application Insights:
Major tranquilizers are used for the treatment of various disorders, such as schizophrenia, bipolar disorder, unipolar depression, dementia and anxiety. Schizophrenia was the largest application segment in 2017 and is expected to grow at a CAGR of XX% over the forecast period owing to increasing prevalence rates coupled with growing awareness about mental health issues and effective treatment options.
Bipolar disorder is another major tranquilizer used for treating manic symptoms like elevated moods along with medication compliance issues that arise in long-term therapy sessions. Growing awareness regarding mental health conditions including bipolar disorder is anticipated to fuel demand over the forecast period.
Regional Analysis:
North America dominated the major tranquilizers market in 2017. The presence of key players, favorable reimbursement policies, and increasing demand for mental health treatment are some of the factors responsible for its largest share. In addition, growing awareness about mental disorders and a rise in consumer preference for tranquillizers over sedatives are expected to drive growth during the forecast period.
Asia Pacific is expected to witness significant growth over the next eight years owing to an increase in consumption rates coupled with rising disposable income levels among individuals suffering from mental disorders such as schizophrenia or bipolar disorder. Furthermore, government initiatives encouraging generic drug manufacturing by Indian companies will further fuel regional market development opportunities during this period.
Growth Factors:
- Increasing prevalence of anxiety disorders and depression is expected to drive the growth of the major tranquilizers market over the forecast period.
- Growing geriatric population is also anticipated to fuel demand for major tranquilizers in the coming years.
- Rising awareness about mental health disorders and their treatment options is projected to boost adoption of these drugs in the near future.
- increasing research and development investments for novel drug therapies are likely to propel growth of this market in forthcoming years . 5) Availability of generic versions of branded drugs would further fuel demand for major tranquilizers during the forecast period
Scope Of The Report
Report Attributes
Report Details
Report Title
Major Tranquilizers Market Research Report
By Type
First Generation, Second Generation, Third Generation
By Application
Schizophrenia, Bipolar Disorder, Unipolar Depression, Dementia, Others
By Companies
Johnson & Johnson, Pfizer, Eli Lilly, Bristol-Myers Squibb, AstraZeneca, GSK, Allergan
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
248
Number of Tables & Figures
174
Customization Available
Yes, the report can be customized as per your need.
Global Major Tranquilizers Market Report Segments:
The global Major Tranquilizers market is segmented on the basis of:
Types
First Generation, Second Generation, Third Generation
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Schizophrenia, Bipolar Disorder, Unipolar Depression, Dementia, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Johnson & Johnson
- Pfizer
- Eli Lilly
- Bristol-Myers Squibb
- AstraZeneca
- GSK
- Allergan
Highlights of The Major Tranquilizers Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- First Generation
- Second Generation
- Third Generation
- By Application:
- Schizophrenia
- Bipolar Disorder
- Unipolar Depression
- Dementia
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Major Tranquilizers Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Major tranquilizers are medications that are used to treat a variety of conditions, including anxiety, insomnia, and depression.
Some of the major players in the major tranquilizers market are Johnson & Johnson, Pfizer, Eli Lilly, Bristol-Myers Squibb, AstraZeneca, GSK, Allergan.
The major tranquilizers market is expected to register a CAGR of 5.5%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Major Tranquilizers Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Major Tranquilizers Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Major Tranquilizers Market - Supply Chain
4.5. Global Major Tranquilizers Market Forecast
4.5.1. Major Tranquilizers Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Major Tranquilizers Market Size (000 Units) and Y-o-Y Growth
4.5.3. Major Tranquilizers Market Absolute $ Opportunity
5. Global Major Tranquilizers Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Major Tranquilizers Market Size and Volume Forecast by Type
5.3.1. First Generation
5.3.2. Second Generation
5.3.3. Third Generation
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Major Tranquilizers Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Major Tranquilizers Market Size and Volume Forecast by Application
6.3.1. Schizophrenia
6.3.2. Bipolar Disorder
6.3.3. Unipolar Depression
6.3.4. Dementia
6.3.5. Others
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Major Tranquilizers Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Major Tranquilizers Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Major Tranquilizers Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Major Tranquilizers Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Major Tranquilizers Demand Share Forecast, 2019-2026
9. North America Major Tranquilizers Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Major Tranquilizers Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Major Tranquilizers Market Size and Volume Forecast by Application
9.4.1. Schizophrenia
9.4.2. Bipolar Disorder
9.4.3. Unipolar Depression
9.4.4. Dementia
9.4.5. Others
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Major Tranquilizers Market Size and Volume Forecast by Type
9.7.1. First Generation
9.7.2. Second Generation
9.7.3. Third Generation
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Major Tranquilizers Demand Share Forecast, 2019-2026
10. Latin America Major Tranquilizers Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Major Tranquilizers Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Major Tranquilizers Market Size and Volume Forecast by Application
10.4.1. Schizophrenia
10.4.2. Bipolar Disorder
10.4.3. Unipolar Depression
10.4.4. Dementia
10.4.5. Others
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Major Tranquilizers Market Size and Volume Forecast by Type
10.7.1. First Generation
10.7.2. Second Generation
10.7.3. Third Generation
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Major Tranquilizers Demand Share Forecast, 2019-2026
11. Europe Major Tranquilizers Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Major Tranquilizers Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Major Tranquilizers Market Size and Volume Forecast by Application
11.4.1. Schizophrenia
11.4.2. Bipolar Disorder
11.4.3. Unipolar Depression
11.4.4. Dementia
11.4.5. Others
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Major Tranquilizers Market Size and Volume Forecast by Type
11.7.1. First Generation
11.7.2. Second Generation
11.7.3. Third Generation
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Major Tranquilizers Demand Share, 2019-2026
12. Asia Pacific Major Tranquilizers Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Major Tranquilizers Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Major Tranquilizers Market Size and Volume Forecast by Application
12.4.1. Schizophrenia
12.4.2. Bipolar Disorder
12.4.3. Unipolar Depression
12.4.4. Dementia
12.4.5. Others
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Major Tranquilizers Market Size and Volume Forecast by Type
12.7.1. First Generation
12.7.2. Second Generation
12.7.3. Third Generation
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Major Tranquilizers Demand Share, 2019-2026
13. Middle East & Africa Major Tranquilizers Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Major Tranquilizers Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Major Tranquilizers Market Size and Volume Forecast by Application
13.4.1. Schizophrenia
13.4.2. Bipolar Disorder
13.4.3. Unipolar Depression
13.4.4. Dementia
13.4.5. Others
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Major Tranquilizers Market Size and Volume Forecast by Type
13.7.1. First Generation
13.7.2. Second Generation
13.7.3. Third Generation
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Major Tranquilizers Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Major Tranquilizers Market: Market Share Analysis
14.2. Major Tranquilizers Distributors and Customers
14.3. Major Tranquilizers Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Johnson & Johnson
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Pfizer
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Eli Lilly
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Bristol-Myers Squibb
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. AstraZeneca
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. GSK
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. Allergan
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. COMPANY8
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. COMPANY9
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. COMPANY 10
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. COMPANY 11
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. COMPANY 12
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
